Med-tech firms raising money in public or private financings, including: Alphatec Holdings.

Biopharmas raising money in public or private financings, including: Adagio, Adial, Pasithea.

Pepgen Inc., a company developing new therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) from its Enhanced Delivery Oligonucleotide platform, has closed an oversubscribed $112.5 million crossover financing. Funds from the round will be used to advance the DMD and DM1 candidates to the clinic in 2022 and 2023, respectively, as well as to expand its Boston-based team. The latest round follows Pepgen’s $45 million series A, led by RA Capital and announced in December 2020.

Med-tech firms raising money in public or private financings, including: Rapid Micro Biosystems, Rxsight, Scivita Medical.

Biopharmas raising money in public or private financings, including: Aardvark, Encellin, Eyevensys, Xinthera.

There’s a lot of competition in the regulatory T cells (Tregs) space and that’s a sign that something good is happening. Sonoma Biotherapeutics Inc. CEO Jeff Bluestone likened it to a typical drive leading to an everyday observation.

Med-tech firms raising money in public or private financings, including: Append Medical, Livanova.

Biopharmas raising money in public or private financings, including: Alzamend, Avidity, Immuneering, Tenaya.